---
title: "Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291140930.md"
description: "A recent underwritten offering successfully raised $50 million, showcasing robust support from institutional investors and improving the company's financial position. This funding will be allocated towards conducting the second Phase 3 HLP003 trial, known as EMBRACE. The trial is crucial for the potential submission of a New Drug Application to the U.S. FDA by 2028."
datetime: "2026-06-29T11:40:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291140930.md)
  - [en](https://longbridge.com/en/news/291140930.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291140930.md)
generator: "portal-rs"
---

# Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results

A recent underwritten offering successfully raised $50 million, showcasing robust support from institutional investors and improving the company's financial position. This funding will be allocated towards conducting the second Phase 3 HLP003 trial, known as EMBRACE. The trial is crucial for the potential submission of a New Drug Application to the U.S. FDA by 2028.

### Related Stocks

- [HELP.US](https://longbridge.com/en/quote/HELP.US.md)
- [CYBN.US](https://longbridge.com/en/quote/CYBN.US.md)

## Related News & Research

- [Cybin announces annual general and special shareholder meeting](https://longbridge.com/en/news/296336431.md)
- [Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results | HELP Stock News](https://longbridge.com/en/news/291139122.md)
- [Helus Pharma Fast-Tracks Phase 3 Enrollment for MDD Drug HLP003](https://longbridge.com/en/news/293390329.md)
- [Is Humacyte (HUMA) Undervalued Following Q2 2026 Earnings And Dialysis Trial Data?](https://longbridge.com/en/news/295760868.md)
- [Bullish Q2 2026 earnings preview](https://longbridge.com/en/news/295688598.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**